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related hospitalization and patient follow-up was calculated based on data from
statistics of the Hospital Remuneration System, the G-DRG hospital payment
scheme and the office-based doctors’ fee scale. The cost caused due to recovery and
disability was estimated based on information from the Federal Statistical Office
and data of the Federal Health Reporting. Experts were interviewed to provide
follow-up resource use information. RESULTS: A total of 78,229 hospitalized leio-
myoma-related cases were treated in year 2009. 80% were hysterectomies, 14%
myomectomies and 6% were related to other therapies. Concerning the therapy
cost per patient, hysterectomy reveals the highest therapy cost, (€5913) followed by
myomectomy (€5793), UAE (€4675) and MR-HIFU (€4311). In a scenario without MR-
HIFU the cost per case accrued to a total of €5840. The budget impact analyse
targeting a patient group between 30 and 45 years of age, reveals a potential cost-
benefit of €1529 per patient if MR-HIFU would be introduced in the SHI system.
CONCLUSIONS: Our results suggest that MR-HIFU due to the administration in the
outpatient sector, the low complication rate and the low disability cost should be
considered as a cost-favourable alternative for the therapy of uterine fibroids.
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OBJECTIVES: The aim of this study was to assess the clinical and economic impact
of malnutrition in post-surgery colorectal cancer patients. METHODS: We per-
formed post-hoc analyses of the data collected in the Alves and al* prospective
study. The following criteria for malnutrition were used: weight loss10% in the 6
months pre-surgery and/or BMI18.5 (pts 70 years) or 21 (pts 70 years). 2
groups (gps) were created a posteriori: Well-Nourished (WN) and Malnourished
(MN) pts. Postoperative morbidity, mortality, hospital length-of-stay (LOS), and
hospital discharge setting were compared between the 2 gps. Individual costs were
valued using the French National Cost Study. We defined 3 scenarios: the most
accurate estimate and the upper and lower possible limits of this estimate. The
economic impact of malnutrition was assessed by calculating the difference in cost
per hospital stay between MN and WN pts. RESULTS: A total of 762 pts were in-
cluded in the analyses. Gps had the same characteristics, except more MN pts
underwent emergent surgery. Complication rate was not significantly different
between the 2 gps; mortality was higher in MN pts (7.4% vs. 4.1%, p0.056) and MN
pts had a mean LOS 3.1 days longer than WN pts (p0.004). A greater proportion of
MN pts could not be discharged and were referred to another facility (69.6% vs.
54.2%, p0.027). Malnutrition impacts the cost per hospital stay by about 3154€ per
patient (most accurate estimate), creating an annual impact of 9,572,770€ for
French public hospitals. CONCLUSIONS: Malnutrition in colorectal cancer surgical
pts is associated with a significant increase of LOS and delays returning home
following hospitalization; both have significant budget impact. Prospective studies
are needed to further investigate this impact and related cost-benefit of (special-
ized) nutritional support in this homogeneous category of patients.
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OBJECTIVES: To examine real world health care utilization (HCU) and costs asso-
ciated with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)
as the initial or only treatment of brain metastasis (BrMets). METHODS: A retro-
spective longitudinal analysis utilized claims data from a national health insurer,
identifying patients18 yrs with2 claims7 days apart for BrMets (ICD-9 198.3x)
from 1/2004-4/2010. The index date was first BrMts claim date. Pre-index period of
6 months and 1 month post-index enrollment (1 month was permitted if due
to death). Patients with primary brain cancers were excluded. HCU and all-cause
per-patient per-month (PPPM) costs were examined. RESULTS: The study included
1,901 and 303 patients who received WBRT or SRS as first or only treatment, with
179d vs. 306d follow-up, respectively. Baseline Charlson comorbidity scores were
similar. Mean age at BrMets diagnosis was higher for WBRT (59yrs) vs. SRS (57yr)
[p-value0.002]. Rates of HCU (events/person-month) were higher among WBRT
vs. SRS patients for office visits (5.29 vs. 3.69), ER visits (0.25 vs. 0.17), and inpatient
stays (0.26 vs. 0.17); rates of outpatient visits were lower among WBRT patients
(2.31 vs. 3.24) [p-value0.001]. Total costs PPPM were higher for the SRS ($20,682) vs.
WBRT cohort ($16,909) [p-value0.005]. Outpatient costs PPPM was the major cost-
driver among the SRS cohort ($8,936, 43% of total) vs. $3,192 (19% of total) for WBRT.
Office costs PPPM contributed most to overall cost among WBRT ($3,428, 20% of
total) vs. $3,053 (18% of total) for SRS. Pharmacy costs PPPM were higher for the SRS
($1,232) vs. WBRT cohort ($692) [p-value 0.001]. CONCLUSIONS: BrMets patients
with SRS incurred higher cost compared to WBRT patients. SRS is recommended
for BrMets patients with 3 lesions and WBRT in 3 lesions may explain longer
survival among SRS patients. Additional studies are augmented to understand
differences.
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OBJECTIVES: To estimate the healthcare resource utilization and their associated
costs secondary to fasciectomy of Dupuytren=s disease treated according with
usual medical practice in public hospital centers in Spain. METHODS: This multi-
center, observational, retrospective cohort study, extracted data through the revi-
sion of medical records of three tertiary public hospitals. Each center should recruit
40 patients which were operated for Dupuytren=s disease, as principal diagnose of
Minimum Data Set, in which the surgical procedure conducted was fasciectomy,
during 2007-2009. To collect all the resources consumed during surgery, a health-
care resource utilization form was designed. Demographic (age, gender, occupa-
tional status), clinical (time of evolution of the pathology and comorbilities) and
healthcare utilization (hospitalizations, medical visits, test, and drugs) data were
collected under medical routine. Unitary costs were provided by e-SALUD and BOT
data base. RESULTS:A total of 123 subjects (86.2% men; 35.8% active workers) were
identified. 17.8% of subjects were diagnose of Dupuytren before year 2000; 8.4%
between 2000-2005 and 73.8% after 2006. 81.3% of patients had at least one comor-
bidity, being hypertension (45%) the most frequent. 71.6% of patients were hospi-
talized in orthopedist (75%) and plastic surgery unit. Mean(SD) length of hospital
stay was 1.5(1.1) days. 28.4% there were operated in ambulatory surgery. All the
patients had follow-up visits after surgery, 27% needed physical therapy, 88% per-
formed preoperative tests and 8% visit the emergency room after surgery. Health-
care mean costs were as follows: fasciectomy €1074(0); hospitalizations €978(743);
ambulatory €186(10); follow-up visits €260(173); emergency rooms €13(53); tests
€132(121); drugs €7(9); physical therapy €46(134). Total cost for patients with Du-
puytren’s disease treated with surgery was €2304(825). There were no significant
differences between the three centers analyzed; p0.181. CONCLUSIONS: This
evaluation suggest that healthcare resources utilization for surgical treatment for
patients with Dupuytren’s disease may cost €2,304(825) per surgery (fasciectomy)
treated under usual medical practice in Spain.
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OBJECTIVES: To examine changes in post-tubal ligation complications and their
associated costs over time.METHODS:Data were obtained from the US i3 Invision™
Data Mart. Data collected spanned the period from January, 2006 through March,
2010. CPT and ICD-9 codes were used to identify patients who received a tubal
ligation as well as a post-tubal ligation complication. Patients were also subcate-
gorized based upon year of tubal ligation (2007, 2008, or 2009) in order to examine if
there were any noticeable trends over time. RESULTS: There were 15,169 women
under age 50 who received a tubal ligation and had continuous insurance coverage
in the 1 year post-tubal ligation. The mean age at tubal ligation was 35.26 years
(SD5.46) with 10.46% having tubal ligation at the time of a pregnancy. Overall,
21.68% (n3,288) of women experienced at least 1 complication, with the most
common being heavy menstrual bleeding (n2,190, 14.44%) and surgical compli-
cations (n729, 4.81%). When assessing changes in complications from 2007-2009,
diagnoses of heavy menstrual bleeding (p0.0003), sepsis (p0.0392), surgical com-
plications (p0.0240), and any complication (p0.0001) all showed statistically sig-
nificant increases over time. Of all women who had a tubal ligation, charges asso-
ciated with the tubal ligation did not increase significantly from 2007-2009;
however, the charge associated with complications did show a statistically signif-
icant increase over the same time period. The average charge for women who
experienced a complication (n3,228) was $37,425 (SD$68,249). CONCLUSIONS:A
substantial number of women experience post-tubal ligation complications and
the charges associated with these complications have increased significantly over
time.
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OBJECTIVES: There are limited data currently available regarding the prevalence of
post-transplant events and associated resource utilization in renal transplant pa-
tients in clinical practice. This study aims to describe the healthcare resource
utilization and costs of managing patients after renal transplantation, stratified by
relative graft functioning status, using observational data from relevant databases
and physician questionnaires from transplant centres across Europe. METHODS:
Data from renal databases in Cardiff and Leuven University Hospitals have been
analysed to assess 3-year post-transplant resource use in the UK and Belgium,
respectively. Similar data have been derived from questionnaires administered in
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multiple centres in UK, Italy, The Netherlands and Poland. For each country, pub-
lished local costs have been applied to the resource use. Results have been strati-
fied by glomerular filtration rate (GFR) at one-year post-transplant. RESULTS:
Across these countries, the total three-year cost of post-transplant care varies
depending on local treatment practices, from a minimum of €36,000 per patient in
Poland to a maximum of €77,000 in the The Netherlands. Consistently across all
countries, the average three-year costs decrease as a result of improved graft func-
tioning status (increased GFR) at one year. The average three-year costs for a pa-
tient with a GFR45 at one year are 29% lower than those with 30GFR in the The
Netherlands, 40% lower in Italy, 43% lower in Belgium, 50% lower in the UK, and
51% lower in Poland. CONCLUSIONS: This study demonstrates that in five Euro-
pean countries, worsening post-transplant renal function contributes to substan-
tive increases in resource use, with some variation across regions. Therefore man-
agement strategies that promote renal function after transplantation are likely to
provide important resource savings. Additional analyses are ongoing in Spain,
Czech Republic, Hungary, Germany and Sweden to further confirm these observa-
tions.
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OBJECTIVES: The main objective of this study is to evaluate the cost-effectiveness
of total hip arthroplasty through anterolateral minimally invasive surgery (MIS)
and compare it with the traditional approach. METHODS: A study was conducted
to compare traditional and minimally invasive surgical techniques for total hip
arthroplasty in a population of 340 patients at two Spanish hospitals (the Virgen de
las Nieves University Hospital of Granada and the Serranía de Ronda Hospital)
during the year 2007. The design of the study was a prospective stochastic cost-
effectiveness analysis, where effectiveness data were collected over a one-year
period at individual patient levels and costs were gathered from the analytical
accounting system of Virgen de las Nieves University Hospital. Effectiveness was
measured in functional terms (clinical) and self-perceived quality of life (SF-12
survey) during the first 6 postoperative weeks. RESULTS: After 6 postoperative
weeks, in comparison with the conventional technique, a pattern in improvements
for MIS was observed for length of hospital stay (hospitalization time was 4.97 days
shorter); for operative time (an average of 83.3 minutes for MIS patients and 97.8
minutes for the control group); and for average length of skin incision (9.83 cm. for
the MIS group and 16.2 cm. for the control group). The total cost of THA with MIS
was lower (4519.19 €) than the cost of traditional hip replacement (6722.46 €). In-
cremental effectiveness value in terms of quality of life was 0.11 points in the SF-12
survey for MIS. The cost-effectiveness analysis reveals a strong dominance of MIS
versus traditional THA. CONCLUSIONS: The study showed that the minimally in-
vasive technique reduces inpatient resource utilization and improves self per-
ceived quality of life of patients compared with the traditional approach. The more
beneficial incremental effectiveness ratio of MIS versus traditional THA supports
the recommendation for expanded use of minimally invasive surgery.
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OBJECTIVES: To perform a comparative cost-effectiveness analysis of Descemet’s
stripping automated endothelial keratoplasty (DSAEK) and penetrating kerato-
plasty (PK) for corneal endothelial disease. METHODS: Systematic review of the
peer-reviewed English literature through a search of PubMed to populate a 5 year
model of a) quality adjusted life years (QALYs) associated with clinical outcomes of
the relatively new DSAEK procedure and the long-established PK procedure, and b)
third party payer (US Medicare 2010) costs associated with associated medical,
surgical and pharmaceutical services. RESULTS: Five year follow-up focusing on
standard therapy and complications yeilds 2.99 QALYs associated with DSEAK and
1.94 QALYs with PK, a difference of 1.05. Following slightly higher sugical costs of
$US7925 for DSEAK and $US7544 for PK, total five year costs are $US10,104 associ-
ated with DSEAK and $US9840 with PK, a difference of $US264. The ICUR is $US251.
Sensitivity analyses of differeing disc dislocation rates, astigmtism complication
rates and cost parameters yield ICURs in the range of $US0 to $US500.
CONCLUSIONS: Using the literature on outcomes and costs for treatments of cor-
neal endothelial disease, a five year model yields robust results siggesting that
DSEAK is slightly more expensive procedure than PK to third party payers, but with
favorable quality adjusted life year resulting making DSEAK a cost-effective option
under all scenarios considered.
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OBJECTIVES: To assess the comparative efficiency of laparoscopic versus open
surgery in colorectal cancer patients. METHODS: To establish relative efficacy of
laparoscopic versus open surgery in all measures that could have clinical or eco-
nomic relevance. Using previous systematic reviews and updating their contents
with the new information published after. Meta-analysis technique is used to sum-
marize the information. A Markov model is developed to estimate progress in time
of health and resource use obtained with these two alternatives. Measures of
health outcomes used in the model were life years and quality adjusted life years.
Probabilistic sensitivity analysis was performed to assess uncertainty in the pa-
rameters included in the Markov model. RESULTS: Preliminary results show that
cost of laparoscopic-assisted surgery is higher than open surgery in close to 750 €.
This difference decreased slightly in the immediate postoperative period due to the
lower readmission rate. The difference in costs, coupled with the equivalence in
long-term results obtained by the two techniques makes that any of them can be
considered efficient for our health system. Since considering a willingness to pay
between 20,000 and 30,000 € per quality-adjusted life year gained, none of the
alternatives have above 60% chance to be the best option. CONCLUSIONS: The
laparoscopic-assisted resection has shown results in terms of overall survival and
recurrence similar to those achieved by open surgery in colorectal surgery patients.
The estimated cost for laparoscopic intervention is slightly higher than open sur-
gery, but seems to accelerate the postoperative recovery time. This implies that
none of the two alternatives is clearly superior to the other in terms of efficiency.
Therefore, each decision maker at hospital level will assess available human and
material resources, and its cost structure to use resources more efficiently.
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OBJECTIVES:A cost-utility analysis was conducted alongside the Danish On-pump
Off-pump Randomization Study (DOORS) based on the intention to treat principle.
METHODS: A post hoc analysis of the problem of missing data was addressed by
multiple imputation using the conditional Gaussian as well as the chained equa-
tion approach. Both methods where applied using two different models (represent-
ing a data-driven respectively a clinical reasoning selection strategy). RESULTS:
The cost-effectiveness acceptability curve for the complete case analysis (n779)
showed 88 % probability of OPCAB being cost-effective at a threshold value of
£30.000 per QALY. In analyses based on the conditional Gaussians approach and
the chained equations approach to multiple imputation the results was 73-75 %.
CONCLUSIONS: The result of the previously published complete-case analysis of
the cost-effectiveness of OPCAB versus CCABG was reinforced by this post hoc
analysis of the uncertainty due to missing data. The analysis showed that the
conditional Gaussian approach and the chained equations approach produced
similar results Evidence about the long term cost-effectiveness of OPCAB versus
CCABG is warranted.
Surgery – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: The high variability on preferences estimates for prostate cancer
could be explained by differences in methods, techniques and obtaining popula-
tions. Our aim was to estimate the preferences and willingness to pay of patients in
the “Spanish Multicenter Study of Localized Prostate Cancer” at 5 years of follow-
up, according to the treatment received (radical prostatectomy, external radiother-
apy and brachytherapy).METHODS:Data analyzed were from the 5-year follow-up
evaluation of the “Spanish Multicenter Study of Localized Prostate Cancer”, in
which patients completed the preference questionnaire. The estimation of prefer-
ences was conducted using the indirect method (from the SF-6D index), and the
direct method using the Standard Gamble (SG) and Time Trade-Off (TTO) tech-
niques. We also assessed the patients’ Willingness-to Pay (WTP). The three treat-
ment groups were compared using the Kruskall Wallis test. RESULTS: Of the 441
patients enrolled, 105 were treated with radical prostatectomy, 137 with external
radiotherapy and 199 with prostate brachytherapy. Most patients were married or
living with a partner (89.6%), were retired (76%) and had completed primary or
secondary studies (53.5%). Utilities measured with the SF-6D showed no statisti-
cally significant differences by treatment group (p  0.356). The utilities measured
by TTO presented the greatest differences according to treatment: mean of 0.94 in
the radical prostatectomy group, 0.99 in external radiotherapy and 0.98 in brachy-
therapy (p 0.001). The willingness to pay also showed significant differences:
mean of 58.4 € in the radical prostatectomy group, 32.04 € in external radiotherapy
and 28.8 € in brachytherapy (p0.01).CONCLUSIONS:The estimates of preferences
vary according to the method and the technique used to obtain them. Both the
utilities obtained by the direct method and the ones through willingness to pay
indicate that radical prostatectomy is the worst valued treatment, prostate brachy-
therapy being the most valued by patients with localized prostate cancer.
PSU21
SPEECH PROBLEM AND HEALTH-RELATED QUALITY OF LIFE IN HEAD AND
NECK CANCER SURVIVORS AFTER FIVE YEARS OF TREATMENTS
Payakachat N1, Suen JY2
A263V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
